SEC Form 4 · accession 0001493152-17-006930
Advaxis, Inc. · ADXS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Petit
Officer — Chief Scientific Officer
Period of report
Jun 19, 2017
Accepted (ET)
Jun 20, 2017 · 6:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100397
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 19, 2017 | A | 57,199 | $0.00 | A | 235,192 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1As part of his long-term incentive compensation, the reporting person was previously granted a performance based restricted stock award by the Compensation Committee. The specific terms of performance, which were required to be achieved prior to earning the award, have now been met. These performance terms were (i) the FDA acceptance of the ADXS-NEO IND, and (ii) the opening of a certain pre-defined number of clinical sites for the AIM2CERV study prior to November 1, 2017. The award vests one-third in November 2017, one-third in November 2018, and will be fully vested in November 2019.